Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 5 beta 1

Integrin alpha 5 beta 1

Brief Information

Name:Integrin alpha-5/beta-1
Target Synonym:Integrin alpha5beta1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data


Biotinylated Human ITGA5&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82Wa) captured on Biotin CAP-Series S Sensor Chip can bind Human Fibronectin with an affinity constant of 4.4 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Human ITGA5&ITGB1 Heterodimer Protein, His Tag&Tag FreeHuman ITGA5&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W5) ELISA bioactivity

Immobilized Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGA5&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W5) with a linear range of 0.2-2 ng/mL (QC tested).

Synonym Name

Integrin alpha 5 beta 1,ITGA5&ITGB1


Integrin alpha 5 beta 1 / Integrin α5β1, which is a major cellular receptor for the extracellular matrix protein fibronectin and plays a fundamental role during mammalian development., is composed of α5 (ITGA5/CD49e) and β1 (ITGB1/CD29) subunits. Integrins are adhesion receptors that transmit bidirectional signals across the plasma membrane. The Integrin alpha 5 beta 1 and its primary extracellular matrix ligand fibronectin (Fn) are of great biological importance.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Recombinant human endostatin (Simcere) YH-16 Approved Jiangsu Simcere Pharmaceutical Co Ltd Endostar, 恩度, Endu Mainland China Carcinoma, Non-Small-Cell Lung Shandong Simcere Bio-Pharmaceutical Co Ltd 2005-09-12 Ascites; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PF-4605412 PF-04605412 Pfizer Pharmaceuticals Ltd (China) Details
BA 015 gene therapy BA-015 Onxeo Details
Pegylated recombinant human endostatin (Tsinghua University) M-2ES; CRB-0401 Phase 1 Clinical Tsinghua University, Beijing Protgen Biotechnology Development Co Ltd, Beijing Proji Pharmaceutical Technology Co Ltd Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Volociximab M-200; Eos-200-4 Pdl Biopharma Details
VAX-014 VAX-014 Phase 1 Clinical Vaxiion Therapeutics Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message